10 October 2011 – trading update

A trading update from the medical diagnostics group has revealed that in the six months to 30 September, revenue is likely to be some 68% higher at £5.53m (2010: £3.30m) with the increase largely down to the acquisition of the allergy business last December.  This increase in revenue is slightly more than expected although the second half performance is likely to depend on the successful roll-out of certain products.  Although the visibility is limited at this stage the directors are confident of prospects and we share this view.  LONG TERM BUY.